Enhancement of Dissolution of Candesartan Cilexetil

The main aim of our investigation was to enhance the dissolution of Candesartan Cilexetil, a prodrug of Candesartan, used in the treatment of hypertension. Candesartan Cilexetil bioavailability is dissolution rate limited. The drug was formulated using various excipients like surfactants, and liquid lipids to improve solubility, dissolution, and hence bioavailability. Method: The solubility of Candesartan Cilexetil was  determined at 25°C by shake flask method and those showing maximum solubility were selected for the formulation of CC. Invitro dissolution studies were done in different media in pH 6.8 phosphate buffer with 1% SLS, tween 20 and 0.1N HCl with 1% SLS. The Surface morphology of LBDDS was studied with SEM and the crystallinity of the drug and the formulation were studied using XRD. Results: CC showed maximum solubility in Transcutol and Labrasol, hence were selected as excipients for the formulation of CC capsules. Drug release was high in 0.1N HCl with 1% SLS and hence was selected as the dissolution medium. The dissolution profile for formulation F5 containing the drug with transcutol and labrasol showed the highest drug release among all formulations i.e., 94.09%. The SEM of the F5 formulation showed that the drug was completely embedded into the lipid matrix and particles were spherical and porous with a size of around 25µ. XRD of formulation F5 indicated the absence of crystallinity in CC capsules containing transcutol and labrasol. Conclusion: It was concluded that CC containing Transcutol and Labrosol significantly increases the solubility and dissolution of the drug